US 11,850,230 B2
Composition for preventing or treating TNF-related diseases, containing novel derivative as active ingredient, and method for inhibiting TNF activity by using same
Tae-Hwe Heo, Gyeonggi-do (KR); and Kye Jung Shin, Seoul (KR)
Assigned to ILAb, Bucheon-si (KR)
Filed by ILAb, Bucheon-si (KR)
Filed on Oct. 6, 2022, as Appl. No. 17/961,472.
Application 17/961,472 is a continuation of application No. 16/757,112, granted, now 11,504,349, previously published as PCT/KR2018/007922, filed on Jul. 12, 2018.
Claims priority of application No. 10-2017-0135899 (KR), filed on Oct. 19, 2017.
Prior Publication US 2023/0099574 A1, Mar. 30, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/352 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01); C07D 311/30 (2006.01)
CPC A61K 31/352 (2013.01) [A61K 9/0056 (2013.01); A61K 45/06 (2013.01); C07D 311/30 (2013.01)] 4 Claims
OG exemplary drawing
 
1. A method for treating a TNF overexpression disease, comprising administering a pharmaceutically effective amount of a composition to a subject in need thereof, wherein the composition comprises
(i) a 4-benzopyranone derivative represented by Formula 1, a pharmaceutically acceptable salt, solvate, racemate, or stereoisomer thereof:

OG Complex Work Unit Chemistry
in which,
R1 is furanyl, thiophenyl, or substituted phenyl represented by

OG Complex Work Unit Chemistry
R3, R4, R5, R6, R7, R8, R9, R10, and R11 are each independently hydrogen, chloro, bromo, fluoro, or methoxyl;
R2 is hydrogen or lower alkyl of (C1-C4);
and
(ii) a drug selected from the group consisting of anti-rheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), steroids, antimetabolites, anti-inflammatory agents, antibiotics, signaling/enzyme inhibitors, receptor inhibitors, HMGB1 inhibitors, antithrombotic drugs, autophagy agonists, cytokine inhibitors, HMG-CoA reductase inhibitors, antihypertensive agents, anticancer agents, immune activation agents, B cell inhibitors, and T cell inhibitors, wherein the TNF overexpression disease is selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, psoriasis, plaque psoriasis, juvenile plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, Behcet's enteritis, ankylosing spondylitis, axial spondyloarthritis, juvenile enthesitis-related arthritis, osteoarthritis, polymyalgia rheumatica, multiple sclerosis, systemic lupus erythematosus, asthma, Sjogren's syndrome, pneumonia, chronic obstructive pulmonary disease, sarcoidosis, granuloma annulare, Wegener's granulomatosis, arteriosclerosis, vasculitis, heart failure, myocardial infarction, kidney injury, nephritis, graft versus host disease, dementia, Alzheimer's disease, Parkinson's disease, pain, uveitis, Behcet's disease, hidradenitis suppurativa, pityriasis rubra pilaris, necrobiosis lipoidica diabeticorum, pyoderma gangrenosum, Sweet's syndrome, subcorneal pustular dermatosis, scleroderma, neutrophilic dermatitis, dermatomyositis, sepsis, and septic shock.